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Introduction {#cam4789-sec-0001}
============

Colorectal cancer (CRC) is a major cause of cancer death worldwide, with over 1.2 million new cases diagnosed each year along with over 600,000 deaths per year [1](#cam4789-bib-0001){ref-type="ref"}. According to GLOBOCAN statistics for Romania 2008, age‐standardized rate for CRC ranked fourth in incidence and third in mortality among all tumor types [1](#cam4789-bib-0001){ref-type="ref"}. Majority of the patients could have relatively good outcomes with 5‐year survival ranging from 50% to 90% [2](#cam4789-bib-0002){ref-type="ref"} depending upon the initial stage of the disease and other prognostic factors. However, although the treatment of CRC definitely improved during the past decades, the 5‐year survival rate for patients with metastatic CRC remains poor. Liver metastasis, which is the most common site for metastatic spread of CRC, is observed in 20--25% of patients at initial diagnosis, and eventually develops after resection of the primary CRC in a further 40--50% of patients [3](#cam4789-bib-0003){ref-type="ref"}. Radical liver resection remains the only potentially curative therapy for patients with CLM, with reported 5‐ and 10‐year actuarial survival rates of 17--35% and 16--23%, respectively [4](#cam4789-bib-0004){ref-type="ref"}. However, most CRC patients with liver metastasis are not candidates for surgical treatment, with the 5‐year survival rate below 10% [5](#cam4789-bib-0005){ref-type="ref"}. Although the prognosis of patients with CLM has been improved by recent advances in multidisciplinary treatments, liver metastasis is still one of the major determinants of survival [6](#cam4789-bib-0006){ref-type="ref"}. Therefore, it is urgently necessary to unravel the underlying molecular mechanisms and genetic alterations that lead to CRC metastases.

Recently, it was reported that miRNA alteration and dysfunction play critical roles during tumorigenesis and metastasis by way of the regulation of cancer cell proliferation, differentiation, apoptosis, and invasion [7](#cam4789-bib-0007){ref-type="ref"}, [8](#cam4789-bib-0008){ref-type="ref"}, [9](#cam4789-bib-0009){ref-type="ref"}. MicroRNAs (miRNAs) belong to a conserved group of short, endogenous, and noncoding RNAs (18--24 nucleotides) that regulate the expression of a wide variety of genes. Through base pairing with the 30‐untranslated region (30‐UTR) of target genes, miRNAs enhance mRNA degradation or inhibit posttranscriptional translation [10](#cam4789-bib-0010){ref-type="ref"}. For instance, miR‐140‐5p inhibits tumor growth and metastasis in hepatocellular carcinoma by targeting TGFBR1 and FGF9 [11](#cam4789-bib-0011){ref-type="ref"}; down‐regulation of miR‐224 and the passenger strand of miR‐221 increase MBD2, suppressing maspin and promoting colorectal tumor growth and metastasis in mice [12](#cam4789-bib-0012){ref-type="ref"}; miR‐137 suppresses CRC invasion and metastasis by way of regulating FMNL2 [13](#cam4789-bib-0013){ref-type="ref"}; miR‐26a plays a role in tumorigenesis and metastasis and have implications to develop new strategies for cancer therapy [14](#cam4789-bib-0014){ref-type="ref"}. Although miRNAs have been extensively investigated in recent years, the molecular regulatory mechanisms of miRNAs and their significance in CLM remain largely unknown and need exploring. In particular, previous studies demonstrated that CRC invasion and metastasis were stimulated by miR‐21 and miR‐103/107 by down‐regulating tumor suppressors PDCD4, and DAPK and KLF4, respectively, but inhibited by miR‐137 and miR‐30a by down‐regulating oncogenes FMNL2 and PIK3CD, respectively [13](#cam4789-bib-0013){ref-type="ref"}, [15](#cam4789-bib-0015){ref-type="ref"}, [16](#cam4789-bib-0016){ref-type="ref"}, [17](#cam4789-bib-0017){ref-type="ref"}.

miRNA‐10b (miR‐10b) has been reported to play a role in the invasion and metastasis of cancer [18](#cam4789-bib-0018){ref-type="ref"}. miR‐10b was initially found highly expressed in metastatic breast cancer cell lines, able to generate metastases when growing as a primary tumor in mice [19](#cam4789-bib-0019){ref-type="ref"}. miR‐10b is also found to be a tumor enhancer in non‐small cell lung cancer (NSCLC), which may represent a potential therapeutic target for NSCLC intervention [20](#cam4789-bib-0020){ref-type="ref"}. Moreover, another study showed that miR‐10b expression is correlated with survival and was a predictor of the poor outcome in patients with esophageal squamous cell carcinoma [21](#cam4789-bib-0021){ref-type="ref"}. Recently, using a large dataset of CRC miRNA and gene expression profiles, miRNA‐10b was found significantly differentially expressed between primary colorectal carcinoma and liver metastases [22](#cam4789-bib-0022){ref-type="ref"}. In this study, we aimed to explore the association between the expression of miR‐10b in CRC and clinicopathological features, and to evaluate its value in prognosis of this tumor.

Materials and Methods {#cam4789-sec-0002}
=====================

Samples and cases {#cam4789-sec-0003}
-----------------

Two hundred and forty‐six pairs of samples (including CRC samples and normal adjacent tissues) from CRC patients were collected from May 2004 to May 2009 at Binzhou Medical University Hospital. None of the patients received chemotherapy or radiotherapy before the surgery. The clinicopathological variables such as gender, age, tumor stage, histological style were analyzed. All samples verified to contain at least 80% tumor cells, and were immediately frozen in liquid nitrogen and stored at −80°C or fixed in 10% formalin for paraffin embedding. Cases with familial adenomatous polyposis CRC were excluded from the study. The miR‐10b quantitative analysis was performed with those samples via real‐time polymerase chain reaction (PCR). The study was approved by the Ethics Committee of Binzhou Medical University Hospital. Written informed consent was obtained for the acquisition and use of patient tissue samples and anonymized clinical data. The diagnosis and histological grade of each case were confirmed by two pathologists independently and based on the clinicopathological criteria described by the UICC.

RNA extraction and qRT‐PCR {#cam4789-sec-0004}
--------------------------

For real‐time PCR analysis of miRNA, the total RNA was extracted from the paraffin embedded tissue samples using the RecoverAll^™^ Total Nucleic Acid Isolation Kit (Applied Biosystems, Foster City, CA) according to the manufacturer\'s instructions. The concentration and purity of the RNA were determined using UV spectrophotometry (A260/A280 ratio of 1.8--2.0). Denaturing agarose gel electrophoresis was also performed to visually assess the RNA, which contained highly abundant 28S and 18S ribosomal RNA bands. Quantitative PCR (qRT‐PCR) was performed using the miScript PCR System (Qiagen, Hilden, Germany) according to the manufacturer\'s instructions. The relative expression was calculated using the comparative cycle threshold (CT) method and normalized to the expression of U6 small nuclear (sn) RNA. The changes in the expression were calculated by the 2 ^−∆∆CT^ method using the equation, relative quantity = 2 ^−∆∆CT^, where ∆∆CT = (CT ^miR−21^--CT ^U6^)~cancer~‐ (CT ^miR−21^--CT ^U6^) ~normal\ adjacent\ tissues~, and CT is the cycle threshold for each specimen.

Statistical analyses {#cam4789-sec-0005}
--------------------

To analyze baseline characteristics, the continuous variables were presented as Mean ± SD and compared between groups by the Student\'s *t*‐tests, and the categorical data were compared by Chi‐square tests. Associations between miR‐10b expression and over survival of the patients with CRC were estimated using adjusted relative risks and 95% confidence intervals (95% CIs) from multivariate logistic regression. Survival time was calculated from the date of CRC diagnosis to the date of death or last follow‐up. Survival analysis was estimated using the Kaplan--Meier method, log‐rank test, and Cox proportional hazards regression model. The *P* \< 0.05 was considered to indicate a statistically significant difference. As previous study found the expression of miR‐10b measured in liver metastasis showed a statistically significant association with the survival of patients affected with stage IV CRC (hazard ratio = 1.47) [22](#cam4789-bib-0022){ref-type="ref"}, the sample size was calculated to be at least 200 each group with a power of 80% and a *P*‐value of 0.05 using a statistical programme (PASS 11). The software of SPSS version 13.0 for Windows (SPSS, Inc., Chicago, IL) was used for statistical analysis.

Results {#cam4789-sec-0006}
=======

miR‐10b expression in CRC tissues {#cam4789-sec-0007}
---------------------------------

miR‐10b expression was detected in 246 pairs of CRC tissues and adjacent nonneoplastic tissues normalized to RNU6B. As shown in Figure [1](#cam4789-fig-0001){ref-type="fig"}, we found that the expression of miR‐10b was markedly increased in CRC tissues compared with nonneoplastic liver tissues (mean ± SD: 7.267 ± 1.286 vs. 3.815 ± 1.692, *P* \< 0.0001, Figure [1](#cam4789-fig-0001){ref-type="fig"}A). When the TNM stage was taken into consideration, the expression levels of miR‐10b were positively correlated with advanced TNM stages (*P* \< 0.0001, Figure [1](#cam4789-fig-0001){ref-type="fig"}B). In addition, the miR‐10b expression of patients diagnosed as CLM at initial involvement (ICLM) was significantly higher than those without liver metastasis (nCLM) (Figure [1](#cam4789-fig-0001){ref-type="fig"}C). Similarly, those patients developed with CLM during follow‐up (FCLM) was also markedly higher than those with nCLM (Figure [1](#cam4789-fig-0001){ref-type="fig"}D).

![miR‐10b expression in colorectal cancer (CRC) and adjacent nonneoplastic tissues detected by quantitative real‐time polymerase chain reaction (qRT‐PCR) analysis.](CAM4-5-2932-g001){#cam4789-fig-0001}

Expression of miR‐10b and clinicopathological features {#cam4789-sec-0008}
------------------------------------------------------

We then analyzed the association between miR‐10b expression and clinicopathological parameters. CRC tissues expressing miR‐10b at levels less than the median expression level (7.29) were assigned to the low expression group (mean expression value 6.23, *n* = 123), and those samples with expression above the median value were assigned to the high expression group (mean expression value 8.30, *n* = 123). The high level of miR‐10b expression was significantly more common in CRC tissues with advanced pathologic grade than those with low pathologic grade (*P* \< 0.0001, Table [1](#cam4789-tbl-0001){ref-type="table-wrap"}). Besides, miR‐10b up‐regulation group has a higher rate of venous infiltration (*P* = 0.007) and lymph node metastasis (*P* = 0.025). No significant association was found between miR‐10b expression and gender, age, or histological type at diagnosis. When the tumor differentiation was taken into consideration, the higher expression of miR‐10b was found in the patients with poor differentiation than in patients with well differentiation (*P* = 0.002).

###### 

Correlation of miR‐10b expression with clinicopathological features of colorectal cancer (CRC) (*n* = 246)

  Clinicopathological features   No. of cases         miR‐10b expression   *P*        
  ------------------------------ -------------------- -------------------- ----- ---- ----------
  Age (year)                     \<60                 88                   46    42   0.690
  ≥60                            158                  77                   81         
  Gender                         Male                 176                  86    90   0.672
  Female                         70                   37                   33         
  TNM stage                      I                    47                   34    13   \<0.0001
  II                             48                   36                   12         
  III                            73                   35                   38         
  IV                             78                   18                   60         
  Tumor Stage                    Early stage (I‐II)   95                   70    25   \<0.0001
  Advanced stage (III‐IV)        151                  53                   98         
  Histological type              Adenocarcinoma       186                  89    97   0.299
  Mucinous adenocarcinoma        60                   34                   26         
  Lymph node metastasis          Positive             173                  78    95   0.025
  Negative                       73                   45                   28         
  Venous invasion                Positive             114                  46    68   0.007
  Negative                       132                  77                   55         
  Differentiation                Poor                 119                  47    72   0.002
  Well                           127                  76                   51         
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###### 

Multivariate analyses of different prognostic parameters in patients with colorectal cancer (CRC) by Cox regression analysis

  Parameter               Risk ratio   95% CI       *P*
  ----------------------- ------------ ------------ ----------
  Age                     1.32         0.52--2.37   0.680
  Gender                  1.25         0.36--3.18   0.796
  Histological type       3.58         1.74--6.16   \<0.001
  Lymph node metastasis   1.94         1.27--4.18   \<0.001
  Venous infiltration     2.55         1.45--5.61   \<0.001
  TNM stage               1.85         1.16--3.64   \<0.001
  Differentiation         5.11         3.68--8.72   \<0.0001
  miR‐10b expression      4.63         2.67‐7.54    \<0.0001

CI, Confidence interval.
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miR‐10b expression and survival in patients with CRC {#cam4789-sec-0009}
----------------------------------------------------

In the 5 years\' follow‐up, the association between miR‐10b expression and prognosis was detected using Kaplan--Meier method and log‐rank test. The overall survival of CRC patients with high miR‐10b expression was significantly shorter than that with low miR‐10b expression (*P* \< 0.0001, Figure [2](#cam4789-fig-0002){ref-type="fig"}A). When the pathological stages were considered, the higher miR‐10b expression was a risk of poor prognosis in both the early stage of (*P* = 0.006, Figure [2](#cam4789-fig-0002){ref-type="fig"}B) and the advanced CRC (*P* = 0.0006, Figure [2](#cam4789-fig-0002){ref-type="fig"}C).

![Kaplan--Meier survival curves for colorectal cancer (CRC) patients with high or low expression of miR‐10b. (A) The 5‐year overall survival rate of all CRC patients with high or low miR‐10b expression; (B) The 5‐year overall survival rate of CRC patients with early stage in high or low miR‐10b expression group; (C) The 5‐year overall survival rate of CRC patients with advanced stage in high or low miR‐10b expression group.](CAM4-5-2932-g002){#cam4789-fig-0002}

Multivariate Cox proportional hazard analysis {#cam4789-sec-0010}
---------------------------------------------

In the Cox proportional hazard model, it was confirmed that miR‐10b expression in the biopsy samples (RR 4.63; 95% CI, 2.67--7.54), differentiation (RR 5.11; 95% CI, 3.68--8.72), tumor stage (RR 1.85; 95% CI, 1.16--3.64), venous infiltration (RR, 2.55; 95% CI, 1.45--5.61), lymph node metastasis (RR 1.94; 95% CI, 1.27--4.18), and histological type (RR 3.58; 95% CI, 1.74--6.16) were predictor of poor prognosis of the patients with CRC. Our results showed that age and gender were not independent predictor of the survival of patients with HCC.

Discussion {#cam4789-sec-0011}
==========

This study investigates the potential clinical utility of miR‐10b to serve as noninvasive prognostic and liver metastasis‐predictive biomarkers in patients with CRC. We observed that miR‐10b expression was up‐regulated in CRC tissues compared with noncancerous tissues. In addition, the miR‐10b expression of patients diagnosed as CLM at initial involvement or during follow‐up was also found markedly higher than those with no liver metastasis. Moreover, the up‐regulation of miR‐10b in CRC cancer tissues was also significantly correlated with aggressive clinicopathological features. We found that the patients with high miR‐10b expression have an advanced tumor staging, higher risk of lymph node metastasis and venous infiltration, and poorer differentiation. The results of Kaplan--Meier analyses showed that CRC patients with the high miR‐10b expression tend to have shorter overall survival and progression‐free survival. The multivariate analysis clearly indicated that the high miR‐10b expression in biopsy samples may be considered as an independent prognostic factor in CRC for decreased survival.

Despite achievements in the treatment in the few past decades, CRC remains a major public health concern, resulting in more than 600,000 deaths each year. The major cause of death and relapse from CRC is metastasis, colorectal tumors often metastasize to the liver and the extent of liver infiltration is a major determinant of survival [23](#cam4789-bib-0023){ref-type="ref"}. Given this, understanding the molecular mechanisms that promote CLM is of crucial significance to the development of therapeutic strategies for CRC patients. However, we have a relatively poor understanding of metastases though significant progress has been made characterizing the molecular features of primary tumors. Studies have found that genetic alterations in tumor cells lead to cellular heterogeneity, which might promote cancer cell invasiveness and colonization in specific organs during the metastatic process. Sequencing reveals that liver metastases may be genetically distinct from primary CRC tumors [24](#cam4789-bib-0024){ref-type="ref"}. However, tumors readily adapt to new microenvironments and many of these changes are reflected in changes in microRNA expression [25](#cam4789-bib-0025){ref-type="ref"}. It has also been revealed that more than 50% of miRNAs are located at tumor‐related genomic regions or in fragile sites [26](#cam4789-bib-0026){ref-type="ref"}. Additionally, a considerable advantage of implementing miRNAs as novel molecular tools derives from the fact that a single miRNA can target and regulate the expression of hundreds of mRNAs. Therefore, it is easier to work with a small number of miRNAs than with mRNAs to discover biomarkers of interest with higher sensitivity and specificity.

The relationship between colorectal liver metastasis and miRNA has been reported. Chen et al. reported that high expression of miR‐103 and miR‐107 was associated with the liver metastasis potential of CRC cell lines and poor prognosis in patients with CRC [16](#cam4789-bib-0016){ref-type="ref"}. Siemens et al. showed that miR‐34a is preferentially down‐regulated via hypermethylation in primary colon cancers, which were associated with distant metastases, whereas miR‐34b/c seems to be silenced irrespective of tumor stage [27](#cam4789-bib-0027){ref-type="ref"}. Hur et al. showed that miR‐200c plays an important role in mediating epithelial--mesenchymal transition and metastatic behavior from CRC to liver [28](#cam4789-bib-0028){ref-type="ref"}. Overexpression of miR‐122 and concomitant suppression of CAT1 in primary tumors appears to play important roles in the development of colorectal liver metastasis [29](#cam4789-bib-0029){ref-type="ref"}. In addition, it was reported in the analysis of clinical samples using quantitative real‐time RT‐PCR that miR‐21, ‐22, and ‐143 participate in colorectal liver metastasis [30](#cam4789-bib-0030){ref-type="ref"}, [31](#cam4789-bib-0031){ref-type="ref"}. The association between miR‐10b was rarely researched in CRC, but elevated miR‐10b expression and poor prognosis were reported in several other tumor types like malignant glioma, pancreatic cancer, and nasopharyngeal carcinoma [32](#cam4789-bib-0032){ref-type="ref"}, [33](#cam4789-bib-0033){ref-type="ref"}, [34](#cam4789-bib-0034){ref-type="ref"}, [35](#cam4789-bib-0035){ref-type="ref"}, [36](#cam4789-bib-0036){ref-type="ref"}, [37](#cam4789-bib-0037){ref-type="ref"}, [38](#cam4789-bib-0038){ref-type="ref"}, [39](#cam4789-bib-0039){ref-type="ref"}. miR‐10b was previously proposed to be positively correlated with metastatic potential of breast cancer cells [19](#cam4789-bib-0019){ref-type="ref"}. Another study by the same group reported reduced pulmonary metastases by silencing of miR‐10b [40](#cam4789-bib-0040){ref-type="ref"}. MicroRNA‐10b overexpression promotes non‐small cell lung cancer cell proliferation and invasion [20](#cam4789-bib-0020){ref-type="ref"}. More recently, increased miR‐10b levels have been associated with bone metastases as well as spread to the lymph nodes [41](#cam4789-bib-0041){ref-type="ref"}, [42](#cam4789-bib-0042){ref-type="ref"}.

The mechanisms of tumor metastasis and invasive functions of miR‐10b appear to be tissue specific and depend upon the expression pattern of its target mRNAs and gene targets in a given cell type. miR‐10b was reported to have a role in regulating angiogenesis in gliomagenesis [35](#cam4789-bib-0035){ref-type="ref"}, [43](#cam4789-bib-0043){ref-type="ref"}. Overexpression of miR‐10b leading to cancer metastasis has also been correlated with the metastasis‐promoting transcription factor Twist which induces epithelial‐to‐mesenchymal transition (EMT) [19](#cam4789-bib-0019){ref-type="ref"}. miR‐10b requires Twist to induce EMT and the resulting cell motility and invasiveness in the breast epithelial cells. E‐cadherin, another important determinant of EMT has also been proposed to be a target of miR‐10b [44](#cam4789-bib-0044){ref-type="ref"}. In addition, miR‐10b has a prominent role in regulating tumor invasion and metastasis by targeting the HOXD10, a transcription factor known for its roles in cellular migration and extracellular modeling such as RhoC, uPAR, *α*3‐integrin, and MT1‐MMP [19](#cam4789-bib-0019){ref-type="ref"}, [45](#cam4789-bib-0045){ref-type="ref"}, [46](#cam4789-bib-0046){ref-type="ref"}, [47](#cam4789-bib-0047){ref-type="ref"}, [48](#cam4789-bib-0048){ref-type="ref"}, [49](#cam4789-bib-0049){ref-type="ref"}. Silencing of miR‐10b significantly increases the levels of HOXD10 to inhibit metastasis [50](#cam4789-bib-0050){ref-type="ref"}. miR‐10b expression has also been shown to correlate with the migration and invasion of human esophageal cancer cell lines through regulation of Kruppel‐like factor 4 (KLF4) expression [51](#cam4789-bib-0051){ref-type="ref"}. Additionally, the reported downstream targets for miR‐10b also include T‐lymphoma invasion and metastasis‐1 factor [52](#cam4789-bib-0052){ref-type="ref"}, stress‐induced cell surface molecule MICB [53](#cam4789-bib-0053){ref-type="ref"}, tat‐interacting protein 30 [34](#cam4789-bib-0034){ref-type="ref"}, etc.

In conclusion, our results have demonstrated that the levels of miR‐10b are higher in CRC tissues than those in matched normal tissues and correlated with disease stage, the presence of lymph node metastasis and venous infiltration, and tumor differentiation. More importantly, the miR‐10b expression of patients diagnosed as CLM at initial involvement or during follow‐up was found markedly higher than those with no liver metastasis. These findings enhance our understanding of the role of miR‐10b in CRC progression and liver metastasis and suggest that miR‐10b may function as microtumor promoter genes in CRC. These findings suggest the potential clinical use of microRNA measurements, particularly in estimating prognosis for patients with CRC. Large well‐designed studies with diverse populations and functional evaluations are warranted to confirm and extend our findings. Examining new targets and other biological experiments will clarify the functions and roles of microRNAs in CLM.
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